JAGX
Jaguar Health, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.60
−14.06%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 27.8M | 11.5M | 11.7M | 9.8M | 12.0M |
| Cost of Revenue | 4.9M | 3.8M | 2.0M | 2.0M | 2.0M |
| Gross Profit | 22.9M | 7.7M | 9.7M | 7.7M | 9.9M |
| Operating Expenses | |||||
| R&D Expense | 25.2M | 25.0M | 16.5M | 18.6M | 17.6M |
| SG&A Expense | 20.9M | 26.0M | 24.0M | 23.0M | 26.7M |
| General & Admin Expense | 17.8M | 21.9M | 16.3M | 16.6M | 17.9M |
| Selling & Marketing Expense | 3.1M | 4.2M | 7.7M | 6.5M | 8.8M |
| Other Expenses | 1.9M | 1.9M | — | 371.0K | — |
| Total Operating Expenses | 48.0M | 52.8M | 40.6M | 42.0M | 44.4M |
| Cost and Expenses | 52.9M | 56.6M | 42.5M | 44.1M | 46.4M |
| Operating Income (EBIT) | (25.1M) | (45.1M) | (30.8M) | (34.3M) | (34.4M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 866.0K | (67.0K) | 231.0K | 6.4M | 12.7M |
| Net Interest Income | (866.0K) | 67.0K | (231.0K) | (6.4M) | (12.7M) |
| Other Non-Op Income/Expense | (11.8M) | (8.9M) | (8.4M) | (7.6M) | (14.0M) |
| Non-Operating Income (excl Interest) | 17.0M | 8.8M | 8.2M | (371.0K) | 1.3M |
| EBT (Pre-Tax Income) | (36.9M) | (54.0M) | (39.3M) | (41.9M) | (48.4M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (36.6M) | (53.4M) | (38.5M) | (41.3M) | (47.5M) |
| Earnings from Cont. Ops | (36.9M) | (54.0M) | (39.3M) | (41.9M) | (48.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (52.6M) | (53.6M) | (38.5M) | (41.3M) | (47.5M) |
| Per Share | |||||
| Basic EPS | ($365.48) | ($803.95) | ($4,574.07) | ($93,992.00) | ($1,899,528.00) |
| Diluted EPS | ($365.48) | ($803.95) | ($4,574.07) | ($93,992.00) | ($1,899,528.00) |
| Revenue Per Share | $34.38 | $172.73 | $1,389.07 | $22,214.46 | $478,585.75 |
| Shares | |||||
| Basic Shares Outstanding | 809122 | 66640 | 8415 | 439 | 25 |
| Diluted Shares Outstanding | 809122 | 66640 | 8415 | 439 | 25 |
| Profitability Metrics | |||||
| EBITDA | (40.1M) | (51.7M) | (36.7M) | (32.8M) | (33.4M) |
| D&A | 2.0M | 2.2M | 2.4M | 1.2M | 2.3M |
| EBIT | (42.1M) | (53.9M) | (39.0M) | (33.9M) | (35.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026